Volume 16
-
No. 4 December 2022
In this issue...• Biopharma deals of 2022
• Exploring the cell and gene landscape
• Uncovering a new generation of microbial-based therapeutics
• Dealmaking for immuno-inflammatory diseases
-
No. 3 September 2022
In this issue...• Oncology’s highest-value deals: top ten
• Mergers and acquisitions in CNS diseases
• Big pharma dominates antibody dealmaking
• Biopharma dealmaking in 2022 so far
-
No. 2 June 2022
In this issue...• Small-molecule drug discovery accelerated by artificial intelligence
• Infectious disease dealmaking refocuses
• The rise of targeted protein degradation
• RNAi therapeutics back on the menu
-
No. 1 March 2022
In this issue...• Molecular diagnostics: exploring financial and partnering trends
• How is the oncology dealmaking landscape shaping up?